

Patient Alert Card

Carry this card with you at all times and show to any medical staff you see

Important Safety Information about Forxiga (dapagliflozin) – for type 1 diabetes only

Signs of DKA include:

Mouth and stomach: Feeling sick or being sick, stomach pain, very thirsty/ dry mouth (signs of dehydration), sweet or metallic taste in your mouth.

Breath, breathing, and smell: Fast and deep breathing, sweet smell to your breath, urine or sweat smells different.

Other signs: Raised level of ketones in urine or blood, rapid weight loss, confusion, feeling unusually sleepy or tired.

If you have signs/symptoms of DKA, talk to a Doctor or go to the hospital straight away and stop taking Forxiga immediately.

Remember:

In patients **taking** Forxiga, DKA can occur even when blood sugar levels are below 14 mmol/L (250 mg/dL). This is called euglycaemic DKA.

AstraZeneca 

**Contact information
for you and your Doctor**



Your name:

Doctor's name:

Doctor's telephone number:

Date Forxiga treatment started:

Relative or friend to contact in an
emergency:

Relative or friend's telephone number:

Information for Doctors, Pharmacists and Nurses



This patient is taking Forxiga (dapagliflozin) for type 1 diabetes mellitus

- It is an adjunct to insulin.
- It is a type of 'SGLT-2 inhibitor'.

Stop Forxiga treatment temporarily before surgical procedures or hospitalisation for serious acute illness.

Assess patients for diabetic ketoacidosis (DKA) straight away if there are signs of DKA.

- Assess for DKA regardless of blood glucose level.
- In patients treated with Forxiga, DKA can occur even when blood glucose levels are below 14 mmol/L (250 mg/dL); called euglycaemic DKA.

Treating DKA

- **If you suspect DKA:** get the patient immediate medical attention and immediately stop Forxiga.
- **Treatment of euglycaemic DKA will require:** extra carbohydrate — in addition to insulin and fluids.

Do not stop or interrupt insulin treatment under any circumstance.

This material, the Patient and Carer Guide, and the Patient Information Leaflet (PIL) are available online at: www.associateddrug.com/frx.pat.mt

18-0010MT DOP: February 2019

AstraZeneca 